Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06735820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

Study acronym: MEKMDM2
StatusRecruiting
PhasePhase 1/2
SponsorAeRang Kim
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date changed from estimate of Oct 1, 2025 to Jun 1, 2026
    • Study sites: 1 to 2
    v3
  2. Start date: Apr 1, 2025 to Oct 1, 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AeRang Kim
1 trial monitored
See all monitored trials
Sarcoma
1,026 trials monitored
See 67 trials at risk
This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and pre-malignant and malignant peripheral nerve sheath tumors
Trial Details
NCT Number NCT06735820
Lead Sponsor AeRang Kim
Collaborators: Children's National Research Institute
Conditions
(from sponsor)		 Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1), Atypical Neurofibroma
Related terms Neurofibromatosis 1, Neurofibrosarcoma
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov